RLMD - Relmada Therapeutics...

Financial Statements of Relmada Therapeutics, Inc.(RLMD), Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various pr

Relmada Therapeutics, Inc.

RLMD

NASDAQ

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

4.52 USD

0.07 (1.55%)

Overview Profile Financial Statements Financial Ratios Chart Analysis News Corporate Actions DCF

All Income Statement Balance Sheet Statement Cash Flow Statement Retained Earning Schedule PPE Schedule Intangible and Goodwill Schedule

FMP

Home Terms of Service Privacy Policy Blog Contact Us

API

Documentation Pricing Formulas Market Indexes

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.